These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
483 related articles for article (PubMed ID: 25677449)
1. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Duffy MJ; McGowan PM; Harbeck N; Thomssen C; Schmitt M Breast Cancer Res; 2014 Aug; 16(4):428. PubMed ID: 25677449 [TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Harbeck N; Kates RE; Gauger K; Willems A; Kiechle M; Magdolen V; Schmitt M Thromb Haemost; 2004 Mar; 91(3):450-6. PubMed ID: 14983219 [TBL] [Abstract][Full Text] [Related]
3. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. Harbeck N; Schmitt M; Kates RE; Kiechle M; Zemzoum I; Jänicke F; Thomssen C Clin Breast Cancer; 2002 Aug; 3(3):196-200. PubMed ID: 12196277 [TBL] [Abstract][Full Text] [Related]
4. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M; J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112 [TBL] [Abstract][Full Text] [Related]
5. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417 [TBL] [Abstract][Full Text] [Related]
6. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. Look MP; van Putten WL; Duffy MJ; Harbeck N; Christensen IJ; Thomssen C; Kates R; Spyratos F; Fernö M; Eppenberger-Castori S; Sweep CG; Ulm K; Peyrat JP; Martin PM; Magdelenat H; Brünner N; Duggan C; Lisboa BW; Bendahl PO; Quillien V; Daver A; Ricolleau G; Meijer-van Gelder ME; Manders P; Fiets WE; Blankenstein MA; Broët P; Romain S; Daxenbichler G; Windbichler G; Cufer T; Borstnar S; Kueng W; Beex LV; Klijn JG; O'Higgins N; Eppenberger U; Jänicke F; Schmitt M; Foekens JA J Natl Cancer Inst; 2002 Jan; 94(2):116-28. PubMed ID: 11792750 [TBL] [Abstract][Full Text] [Related]
7. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C; Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655 [TBL] [Abstract][Full Text] [Related]
8. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Harbeck N; Kates RE; Schmitt M; Gauger K; Kiechle M; Janicke F; Thomassen C; Look MP; Foekens JA Clin Breast Cancer; 2004 Dec; 5(5):348-52. PubMed ID: 15585071 [TBL] [Abstract][Full Text] [Related]
10. The urokinase plasminogen activator system: role in malignancy. Duffy MJ Curr Pharm Des; 2004; 10(1):39-49. PubMed ID: 14754404 [TBL] [Abstract][Full Text] [Related]
11. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Duffy MJ Clin Chem; 2002 Aug; 48(8):1194-7. PubMed ID: 12142372 [TBL] [Abstract][Full Text] [Related]
12. uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Annecke K; Schmitt M; Euler U; Zerm M; Paepke D; Paepke S; von Minckwitz G; Thomssen C; Harbeck N Adv Clin Chem; 2008; 45():31-45. PubMed ID: 18429492 [TBL] [Abstract][Full Text] [Related]
13. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact. Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533 [TBL] [Abstract][Full Text] [Related]
14. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647 [TBL] [Abstract][Full Text] [Related]
15. Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer. Pusina S Med Arch; 2018 Nov; 72(5):335-340. PubMed ID: 30524164 [TBL] [Abstract][Full Text] [Related]
16. Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers. Duffy MJ Biochem Soc Trans; 2002 Apr; 30(2):207-10. PubMed ID: 12023852 [TBL] [Abstract][Full Text] [Related]
17. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061 [TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel. Kantelhardt EJ; Vetter M; Schmidt M; Veyret C; Augustin D; Hanf V; Meisner C; Paepke D; Schmitt M; Sweep F; von Minckwitz G; Martin PM; Jaenicke F; Thomssen C; Harbeck N BMC Cancer; 2011 Apr; 11():140. PubMed ID: 21496284 [TBL] [Abstract][Full Text] [Related]
19. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Duffy MJ; Duggan C Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235 [TBL] [Abstract][Full Text] [Related]
20. Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer. Harms W; Malter W; Krämer S; Drebber U; Drzezga A; Schmidt M Anticancer Res; 2014 Aug; 34(8):4457-62. PubMed ID: 25075085 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]